IntraCranial Angiography-derived Fraction Flow-guided Percutaneous Transluminal Angioplasty and Stenting Versus Medical Therapy (ICAS-MT)

Overview

A multicenter, open-label, blinded-endpoint, prospective, randomized controlled clinical trial with an "all comers" design.

Detailed description

The main objective of this study is to investigate the impact of angiography-derived fractional flow (Angio-FF) on diagnostic and therapeutic decision-making in patients with symptomatic intracranial atherosclerotic stenosis (sICAS). The study aims to evaluate whether stenting plus medical therapy, compared to medical therapy alone, can benefit patients selected through Angio-FF screening.

For Group A, patients with significant stenosis and hemodynamic impairment identified through Angio-FF (≤0.7) screening are expected to have a higher risk. The patients will be enrolled in RCT trial, with a planned enrollment of 336 subjects.

For Group B, patients with significant stenosis but without hemodynamic impairment identified through Angio-FF (\>0.7) screening will be included in the registry cohort, with a planned enrollment of 200 subjects.

Interventions

• Combination product Stenting plus medical therapy
  Patients randomized to intervention group received the percutaneous transluminal balloon angioplasty with stenting within 5 days after randomization, and loading dose of aspirin and clopidogrel was allowed. Received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after procedure.
• Drug Medical therapy alone
  Medical therapy alone: received aspirin, 100mg, plus clopidogrel, 75 mg, daily for 90 days after randomisation.

Primary outcome measures

• Stroke or death [Time frame: Stroke or death within 30 days after enrollment; Or stroke in the territory of the symptomatic intracranial artery (SIT) between 30 days and 1 year.]

Secondary outcome measures (7)

• Ischemic stroke in the target vessel territory [Time frame: Within 1-3 years after enrollment]
• Ischemic stroke in non-target vessel territory [Time frame: Within 30 days to 1 year, and within 1-3 years after enrollment]
• Any occurrence of cerebral hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage [Time frame: Within 30 days to 3 years after enrollment]
• Any cause of death [Time frame: Within 30 days to 3 years after enrollment]
• mRS score [Time frame: At 1 year, 2 years, and 3 years after enrollment]
• National Institutes of Health Stroke Scale (NIHSS) score [Time frame: At 1 year, 2 years, and 3 years after enrollment]
• Barthel Index [Time frame: At 1 year, 2 years, and 3 years after enrollment]

Eligibility criteria

Inclusion criteria

• Age ≥30 and ≤80 years old.
• Symptomatic intracranial atherosclerotic stenosis: Transient ischemic attack (TIA) or stroke related to 70%-99% stenosis in the major intracranial arteries (intracranial segment of the internal carotid artery, M1 segment of the middle cerebral artery, V4 segment of the vertebral artery, and basilar artery) within the past 3 months.
• Only one target vessel with 70-99% stenosis confirmed by angiography for enrollment in the trial (WASID criteria).
• Patients with ischemic stroke should be performed with stenting beyond a duration of 2 weeks from the latest ischemic symptom onset, patients with TIA have no time restriction.
• Pre-enrollment modified Rankin Scale (mRS) score ≤2.
• Target vessel reference diameter must be measured to be 2 mm to 4.5 mm, target area of stenosis is less than or equal to 14mm in length.
• Patients required to meet at least with one atherosclerotic risk factors, including hypertension, diabetes, hyperlipidemia, hyperhomocysteinemia, coronary heart disease, obesity, smoking history, and atherosclerosis in other arterial vessels.
• Negative pregnancy test in a female who has had any menses in the last 18 months.
• Patient is willing and able to return for all follow-up visits required by the protocol.
• Patient understands the purpose and requirements of the study, can make him/herself understood, and has provided informed consent.

Exclusion criteria

• Intracranial arterial stenosis not caused by atherosclerotic lesions, such as arterial dissection, moya-moya disease, vasculitic disease, viral vascular lesions (e.g., herpes zoster, varicella), neurosyphilis, other intracranial infections, radiation-induced vasculopathy, fibromuscular dysplasia, sickle cell disease, neurofibromatosis, benign central nervous system vascular diseases, postpartum angiopathy, suspected vasospastic process, suspected recanalized embolus, etc.
• Any conditions that precludes proper angiographic assessment.
• Preoperative MRI indicating only lacunar infarction in the target lesion territory.
• History of subarachnoid hemorrhage, subdural or epidural hematoma within 30 days prior to enrollment, or untreated chronic subdural hematoma thickness≥5mm, or history of primary intracerebral hemorrhage.
• At risk of hemorrhagic transformation during the procedure (CT or MRI showing infarct area diameter >5 cm); hemorrhagic transformation of an ischemic stroke within the past 15 days (detected by CT).
• Tandem extracranial or intracranial stenosis (70%-99%) or occlusion that is proximal or distal to the target intracranial lesion
• Bilateral intracranial vertebral artery stenosis of 70%-99% and uncertainty about which lesion is symptomatic (for example, if patient has pon, midbrain, temporal and occipital symptoms).
• Stenting, angioplasty, or endarterectomy of an extracranial (carotid or vertebral artery) or intracranial artery within 30 days prior to expected enrollment date.
• Previous treatment of target lesion with a stent, angioplasty, or other mechanical device, or plan to perform staged angioplasty followed by stenting of target lesion
• Severe vascular tortuosity, severe calcification, or other factors that would preclude the safe introduction of a guiding catheter, guiding sheath or stent placement.
• Presence of intraluminal thrombus proximal to or at the target lesion.
• Any aneurysm proximal to or distal to intracranial stenotic artery.
• Intracranial tumors or any intracranial vascular malformations.
• Potential cardiac sources of emboli such as atrial fibrillation, left ventricular thrombus, heart valve replacement, atrial septal defect, ventricular septal defect, atrial myxoma, etc.
• Myocardial infarction within previous 30 days.
• Suspected severe allergy or contraindication to vascular interventional-related drugs or devices, such as aspirin, clopidogrel, general anesthesia agents, heparin, contrast agents, nitinol alloy, etc.
• Active bleeding diathesis or coagulopathy, active gastrointestinal ulcer, major systemic hemorrhage within 30 days, active bleeding diathesis, platelets count <100,000, hematocrit <30, INR >1.5, dysfunctions of the blood coagulation system.
• uncontrolled severe hypertension (systolic BP>180mm Hg or diastolic BP>110mm Hg)
• Severe comorbidities or unstable conditions, such as severe heart failure, respiratory failure, or renal failure (serum creatinine>264μmol/L, unless on dialysis), severe liver dysfunction (ALT or ALT >3 times normal), malignant tumors.
• Major surgery performed within 30 days prior to enrollment or planned inpatient surgery within 90 days after enrollment.
• Pregnancy or intent to become pregnant during the trial period.
• Currently participating in another clinical trial.
• Life expectancy less than 3 years
• Patients unable to complete follow-up due to cognitive impairment, emotional disorders, or mental illness.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Single blind

Primary purpose

Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT05974033 · ICAS-MT

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗